Concepedia

Publication | Open Access

Immunogenicity, Safety, and Immune Persistence of a Novel Inactivated Human Enterovirus 71 Vaccine: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial

DOIFull Paper Access

52

Citations

29

References

2013

Year

Yanping Li, Zhenglun Liang, Jielai Xia, Junyu Wu, Ling Wang, Li-Fei Song, Qunying Mao, Shu-Qun Wen, Ren-Guo Huang, Yuansheng Hu,
The Journal of Infectious Diseases

Abstract

The 400 U dose was recommended as the optimal dose for the phase III trial because of its good safety profile and higher immunogenicity.

References

YearCitations

Page 1